| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| Other Sizes |
| Targets |
4-iodo-SAHA targets class I and class II histone deacetylases (HDACs). It binds the zinc ion in the catalytic site of HDACs and inhibits their deacetylase activity. This leads to increased histone acetylation, chromatin remodeling, and re-expression of silenced tumor suppressor genes. It induces apoptosis and inhibits cell proliferation. It also suppresses HDAC7.
|
|---|---|
| ln Vitro |
4-Iodo-SAHA (0.1-100 μM; 48 h) suppresses the HT29, JA16, HL60, U937, and Skbr3 cell lines[1].
4-Iodo-SAHA (2 μM; 6-24 h) modifies the levels of p21 and acetylated H4 in SKBR3 cells[1]. In vitro, 4-iodo-SAHA inhibits class I and class II HDACs with EC50 values of 1.1, 0.95, 0.12, 0.24, and 0.85 µM for Skbr3, HT29, U937, JA16, and HL60 cells, respectively. It is 10-fold more potent than SAHA in inhibiting U937 cell proliferation. It induces apoptosis and elevates histone acetylation. It suppresses HDAC7 and resensitizes drug-resistant cells. |
| ln Vivo |
4-Iodo-SAHA (1k) (50 mg/kg; p.o. five times weekly for two weeks) exhibits comparable toxicity to both SAHA-treated and control mice[1].
In vivo, 4-iodo-SAHA is orally active and has antiproliferative activity in various cancer cell lines. It is a promising monotherapy candidate warranting further investigation in advanced disease settings. It has not been approved for therapeutic use. |
| Enzyme Assay |
For non-cell enzyme assays, recombinant HDACs are incubated with 4-iodo-SAHA and a fluorogenic acetyl-lysine substrate. Deacetylase activity is measured by fluorescence release. IC50 values are calculated from dose-response curves. Selectivity is assessed against different HDAC isoforms.
|
| Cell Assay |
Cell Line: SKBR3, HT29, U937, JA16 and HL60 cell lines
Concentration: 0.1-100 μM Incubation Time: 48 h Result: Inhibited SKBR3, HT29, U937, JA16 and HL60 cell lines with EC50s of 1.1, 0.95, 0.12, 0.24, 0.85 and 1.3 μM , respectively. Showed 10-fold potent as an inhibitor of U937 cell line compared to SAHA. In cell assays, cancer cell lines (e.g., U937, SKBR3, HT29) are treated with serial dilutions of 4-iodo-SAHA. Cell viability is measured by MTT or SRB. Apoptosis is assessed by Annexin V staining or caspase-3 activity. Histone acetylation is measured by Western blot. HDAC7 expression is measured by Western blot. |
| Animal Protocol |
8-week-old fvb mice
50 mg/kg Oral gavage; 50 mg/kg five times per week; for 2 weeks In vivo animal protocols use mice bearing tumor xenografts. 4-iodo-SAHA is dissolved in DMSO/PEG/saline and administered orally at doses of 10-100 mg/kg. Tumor volume is measured twice weekly. Tumor tissue is analyzed for histone acetylation and apoptosis markers. Pharmacokinetic parameters are determined by LC-MS. |
| References |
| Molecular Formula |
C14H19N2O3I
|
|---|---|
| Molecular Weight |
390.21626
|
| Exact Mass |
390.044
|
| CAS # |
1219807-87-0
|
| PubChem CID |
46205754
|
| Appearance |
White to off-white solid
|
| Density |
1.6±0.1 g/cm3
|
| Index of Refraction |
1.616
|
| LogP |
2.49
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
20
|
| Complexity |
305
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ONC(CCCCCCC(NC1=CC=C(I)C=C1)=O)=O
|
| InChi Key |
BYVHZKAHBXINPL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H19IN2O3/c15-11-7-9-12(10-8-11)16-13(18)5-3-1-2-4-6-14(19)17-20/h7-10,20H,1-6H2,(H,16,18)(H,17,19)
|
| Chemical Name |
N'-hydroxy-N-(4-iodophenyl)octanediamide
|
| Synonyms |
4-iodo-SAHA; ISAHA
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5627 mL | 12.8133 mL | 25.6266 mL | |
| 5 mM | 0.5125 mL | 2.5627 mL | 5.1253 mL | |
| 10 mM | 0.2563 mL | 1.2813 mL | 2.5627 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
